Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
Kin Seng LiemMargo J H van CampenhoutQing XieWillem Pieter BrouwerHeng ChiXun QiLiang ChenFehmi TabakBettina E HansenHarry L A JanssenPublished in: Alimentary pharmacology & therapeutics (2020)
PEG-IFN add-on to ETV therapy was associated with higher response compared to ETV monotherapy in patients with HBeAg positive CHB. Response doubled in PEG-IFN naive patients with HBsAg below 4000 IU/mL and HBV DNA below 50 IU/mL, and therefore identifies them as the best candidates for PEG-IFN add-on (Identifiers: NCT00877760, NCT01532843).